search
Back to results

Safety and Efficacy Registry of Yinyi Stent (SERY-I)

Primary Purpose

Coronary Artery Disease

Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Yinyi stent
Sponsored by
Shanghai Jiao Tong University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Disease

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • age 18-80 years old
  • both gender
  • native coronary lesion
  • narrowing > 70%
  • vessel size 2.5-4.0 in diameter

Exclusion Criteria:

  • without informed consent,
  • ST elevation myocardial infarction within 7 days,
  • patient with ≤ 70% coronary narrowing at target lesion,
  • left main lesion,
  • multivessel narrowing need more than 3 stent implantations,
  • by-pass graft,
  • abnormal liver function before randomization,
  • active hepatitis or muscular disease,
  • impaired renal function with serum creatinine level > 3mg/dl,
  • impaired left ventricular function with LVEF < 30%,
  • Participate in other studies.

Sites / Locations

  • ruijin hospital, Shanghai Jiao Tong University, School of Medicine

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Yinyi stent

Arm Description

subjects with Yinyi stent implantation

Outcomes

Primary Outcome Measures

major adverse cardiac events
including cardiac death, myocardial infarction and target vessel failure

Secondary Outcome Measures

stent thrombosis
according to ARC definition

Full Information

First Posted
April 1, 2011
Last Updated
July 27, 2015
Sponsor
Shanghai Jiao Tong University School of Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT01373645
Brief Title
Safety and Efficacy Registry of Yinyi Stent
Acronym
SERY-I
Official Title
Safety and Efficacy Registry of Yinyi Polymer-free Paclitaxel-eluting Stent
Study Type
Interventional

2. Study Status

Record Verification Date
October 2008
Overall Recruitment Status
Completed
Study Start Date
January 2009 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
December 2011 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Shanghai Jiao Tong University School of Medicine

4. Oversight

5. Study Description

Brief Summary
Drug-eluting stents effectively reduce restenosis but may increase late thrombosis and delayed restenosis. Persistent polymer could be responsible. Local delivery of paclitxel from a polymer-free Yinyi stent (Dalian Yinyi biomaterial research and development co.ltd) may prevent these complications.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
1045 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Yinyi stent
Arm Type
Experimental
Arm Description
subjects with Yinyi stent implantation
Intervention Type
Device
Intervention Name(s)
Yinyi stent
Intervention Description
subjects with Yinyi stent implantation
Primary Outcome Measure Information:
Title
major adverse cardiac events
Description
including cardiac death, myocardial infarction and target vessel failure
Time Frame
12 months
Secondary Outcome Measure Information:
Title
stent thrombosis
Description
according to ARC definition
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age 18-80 years old both gender native coronary lesion narrowing > 70% vessel size 2.5-4.0 in diameter Exclusion Criteria: without informed consent, ST elevation myocardial infarction within 7 days, patient with ≤ 70% coronary narrowing at target lesion, left main lesion, multivessel narrowing need more than 3 stent implantations, by-pass graft, abnormal liver function before randomization, active hepatitis or muscular disease, impaired renal function with serum creatinine level > 3mg/dl, impaired left ventricular function with LVEF < 30%, Participate in other studies.
Facility Information:
Facility Name
ruijin hospital, Shanghai Jiao Tong University, School of Medicine
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200025
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
22340171
Citation
Zhang RY, Zhang Q, Zhu JZ, Chen LL, Zhang CY, Zhou XC, Yuan Y, Zhong ZX, Li L, Qiu J, Wang W, Chen XM, Yang ZJ, Yan JC, Chen SL, Hou YQ, Wu YQ, Luo HM, Qiu JP, Zhu L, Wang Y, Fu GS, Wang JA, Ma KH, Yin YH, Zhang DF, Hu XS, Zhu GY, Shen WF; Safety and Efficacy Registry of Yinyi stent (SERY-I) Investigators. Safety and efficacy of polymer-free paclitaxel-eluting microporous stent in real-world practice: 1-year follow-up of the SERY-I registry. Chin Med J (Engl). 2011 Nov;124(21):3521-6. No abstract available.
Results Reference
result

Learn more about this trial

Safety and Efficacy Registry of Yinyi Stent

We'll reach out to this number within 24 hrs